Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial

Published:2024-08-20 Issue:24 Volume:42 Page:2849-2852
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Einstein David J.¹²^ORCID,Regan Meredith M.²³,Stevens Julia S.⁴,McDermott David F.¹²,Madan Ravi A.⁵

Affiliation:

1. Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA

2. Harvard Medical School, Boston, MA

3. Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA

4. Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA

5. Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Abstract

What is most important to patients with BCR prostate cancer? Metastasis-free versus treatment-free survival.

Publisher

American Society of Clinical Oncology (ASCO)

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.24.00279

Reference19 articles.

1. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

2. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

3. The effect of PSA doubling time (PSADT) and Gleason score on the PSA at the time of initial metastasis in men with biochemical recurrence after prostatectomy.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to B. Tombal et al;Journal of Clinical Oncology;2024-09-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP